drugset / Trial / NCT04899908
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
Phase 2
Recruiting
134 enrolled
Brigham and Women's Hospital
Dana-Farber Cancer Institute · collabTherAguix · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to determine whether AGuIX (Activation and Guidance of Irradiation by X-ray) gadolinium-based nanoparticles make radiation work more effectively in the treatment of patients with brain metastases that are more difficult to control with stereotactic radiation alone.
Timeline
- Start
- 2021-09-15
- Primary completion
- 2028-04
- Completion
- 2029-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AGuIX | Other / unclassified | 100 mg/kg | Intravenous |